6.	ACCRUED EXPENSES

Accrued expenses consisted of the following:

 

		As of December 31,
		2015				2014
Accrued compensation		$	758			$	814
Accrued clinical expenses			138				384
Accrued fees for technology transfer agreement			—				350
Accrued other			548				128
Accrued expenses due to Intrexon			1,546				7
Total accrued expenses		$	2,990			$	1,683

On April 15, 2014, the Company entered into a technology transfer agreement with a collagen manufacturer for a non-exclusive, non-transferable, non-sublicensable perpetual, irrevocable, worldwide, royalty-free right and license to use its proprietary process to make Type 1 bovine collagen. Pursuant to the agreement, the Company paid fees of $400 and will pay additional fees totaling $350. In addition, the Company has agreed to reimburse the collagen manufacturer for mutually agreed upon expenses in connection with such technology. This agreement will remain in effect until either party provides written notice to terminate the agreement.